C Number:

Study Gender:

PWG Approval Date

PA10R: Statistical Analysis of Non-Neoplastic Lesions with Litter Incidence

Test Compound: 2-Ethylhexyl p-Methoxycinnamate CAS Number: 5466-77-3 Date Report Requested: 01/14/2020 Time Report Requested: 10:32:51 Lab: RTI

MOG003B

Both See web page for date of PWG Approval

PA10R: Statistical Analysis of Non-Neoplastic Lesions with Litter Incidence

Test Compound: 2-Ethylhexyl p-Methoxycinnamate

	F0 Female				
	Treatment Groups (ppm)				
	0	1000	3000	6000	
Disposition Summary					
Animals Initially In Study	26	26	26	26	
Early Deaths					
Unscheduled Sacrifice	1			1	
Scheduled Deaths					
Scheduled sacrifice, terminal (LD 28, SD 24 - 27)	25	26	26	25	
Number of Animals Examined	3		1	1	
ALIMENTARY SYSTEM					
LIVER	(3)	(0)	(0)	(0)	
HEPATODIAPHRAGMATIC NODULE	1 (33.3%)				
CARDIOVASCULAR SYSTEM					
None					
ENDOCRINE SYSTEM					
None					
GENERAL BODY SYSTEM					
None					
GENITAL SYSTEM					
None					
HEMATOLYMPHOID SYSTEM					
None					
INTEGUMENTARY SYSTEM					
None					

Study Number: MOG003B Test Type: MOG Route: Dosing in Feed Species/Strain: Rat/Sprague-Dawley	PA10R: Statistical Analysis of Non-Neoplastic Lesions with Litter Incidence Test Compound: 2-Ethylhexyl p-Methoxycinnamate CAS Number: 5466-77-3		Date Report Requested: 01/14/2020 Time Report Requested: 10:32:51 Lab: RTI		
		F0 Female			
			Treatment Groups	(ppm)	
		0 1000			6000
MUSCULOSKELETAL SYSTEM None					
NERVOUS SYSTEM None					
RESPIRATORY SYSTEM None					
SPECIAL SENSES SYSTEM EYES RETINA; ATROPHY		(0)	(0)	(0)	(1) 1 (100%)
URINARY SYSTEM None					

PA10R: Statistical Analysis of Non-Neoplastic Lesions with Litter Incidence

Test Compound: 2-Ethylhexyl p-Methoxycinnamate

CAS Number: 5466-77-3

	Treatment Groups (ppm)				
	0	1000	3000	6000	
Disposition Summary					
Animals Initially In Study	10	10	10	10	
Early Deaths					
Scheduled Deaths					
Scheduled sacrifice, terminal (PND 110 - 112)	10	10	10	10	
Number of Animals Examined	10	1	2	10	
Total number litters	10	1	2	10	
LIMENTARY SYSTEM					
INTESTINE, ILEUM	(10)	(0)	(0)	(10)	
PEYERS PATCH; HYPERPLASIA; LYMPHOCYTE				1 (10%) [1]	
LIVER	(10)	(0)	(1)	(10)	
HEPATODIAPHRAGMATIC NODULE	1 (10%) [1]				
INFILTRATION CELLULAR; MONONUCLEAR CELL	1 (10%) [1]			1 (10%) [1]	
INFLAMMATION; FOCAL				1 (10%) [1]	
HEPATOCYTE; CENTRILOBULAR; NECROSIS			1 (100%) [1]		
STOMACH, FORESTOMACH	(10)	(0)	(0)	(10)	
EPITHELIUM; HYPERPLASIA; DIFFUSE	1 (10%) [1]				
MUSCULARIS; MINERAL	1 (10%) [1]				
STOMACH, GLANDULAR	(10)	(0)	(0)	(10)	
GLANDS; DILATION	2 (20%) [2]			2 (20%) [2]	
CARDIOVASCULAR SYSTEM					
HEART	(10)	(0)	(0)	(10)	
CARDIOMYOPATHY	4 (40%) [4]			1 (10%) [1]	
EPICARDIUM; INFLAMMATION, CHRONIC	1 (10%) [1]			2 (20%) [2]	

Test Compound: 2-Ethylhexyl p-Methoxycinnamate

CAS Number: 5466-77-3

	Treatment Groups (ppm)				
	0	1000	3000	6000	
ADRENAL CORTEX	(10)	(0)	(0)	(10)	
UNILATERAL; HYPERPLASIA	1 (10%) [1]				
THYROID GLANDS	(10)	(0)	(0)	(10)	
UNILATERAL; CYST	1 (10%) [1]				
BILATERAL; ECTOPIC TISSUE, THYMUS	1 (10%) [1]				
ECTOPIC TISSUE, THYMUS				2 (20%) [2]	

Test Compound: 2-Ethylhexyl p-Methoxycinnamate

CAS Number: 5466-77-3

		Treatment G	roups (ppm)	
	0	1000	3000	6000
GENITAL SYSTEM				
EPIDIDYMIDES	(10)	(1)	(0)	(10)
DUCT; UNILATERAL; EXFOLIATED GERM CELL		1 (100%) [1]		
UNILATERAL; HYPOSPERMIA		1 (100%) [1]		
BILATERAL; INFILTRATION CELLULAR; MONONUCLEAR CELL	2 (20%) [2]			1 (10%) [1]
UNILATERAL; INFILTRATION CELLULAR; MONONUCLEAR CELL	4 (40%) [4]			1 (10%) [1]
EPITHELIUM; BILATERAL; VACUOLATION	2 (20%) [2]			2 (20%) [2]
PREPUTIAL GLANDS	(10)	(0)	(0)	(10)
DUCT; BILATERAL; DILATION				1 (10%) [1]
DUCT; UNILATERAL; DILATION	1 (10%) [1]			2 (20%) [2]
UNILATERAL; INFLAMMATION, CHRONIC	2 (20%) [2]			1 (10%) [1]
BILATERAL; INFLAMMATION, SUPPURATIVE				1 (10%) [1]
UNILATERAL; INFLAMMATION, SUPPURATIVE	1 (10%) [1]			
TESTES	(10)	(1)	(0)	(10)
GERMINAL EPITHELIUM; UNILATERAL; ATROPHY	1 (10%) [1]	1 (100%) [1]		1 (10%) [1]
INTERSTITIUM; UNILATERAL; EDEMA		1 (100%) [1]		
VENTRAL PROSTATE	(10)	(0)	(0)	(10)
BILATERAL; INFILTRATION CELLULAR; MONONUCLEAR CELL	1 (10%) [1]			2 (20%) [2]
UNILATERAL; INFILTRATION CELLULAR; MONONUCLEAR CELL	2 (20%) [2]			1 (10%) [1]
BILATERAL; INFLAMMATION, CHRONIC	3 (30%) [3]			4 (40%) [4]
HEMATOLYMPHOID SYSTEM				
THYMUS	(10)	(0)	(0)	(10)
EPITHELIUM; HYPERPLASIA	1 (10%) [1]			1 (10%) [1]

Study Number: MOG003BP.Test Type: MOGRoute: Dosing in FeedSpecies/Strain: Rat/Sprague-Dawley	PA10R: Statistical Analysis of Non-Neoplastic Lesions with Litter Incidence Test Compound: 2-Ethylhexyl p-Methoxycinnamate CAS Number: 5466-77-3		Date Report Requested: 01/14/2020 Time Report Requested: 10:32:51 Lab: RTI	
	F1 Male : Subchronic Male			
		Treatment Group	s (ppm)	
	0	1000	3000	6000
MUSCULOSKELETAL SYSTEM None				
NERVOUS SYSTEM None				
RESPIRATORY SYSTEM				
LUNG BRONCHIOLE; HYPERPLASIA; NEUROENDOCRINE ALVEOLUS; INFILTRATION CELLULAR, HISTIOCYTI INFLAMMATION, ACUTE PLEURA; INFLAMMATION, CHRONIC SUBPLEURAL; INFLAMMATION, CHRONIC	. , ,	(0)	(0)	(10) 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] 1 (10%) [1]
NOSE TURBINATE; FOREIGN BODY	(0)	(0)	(0)	(1) 1 (100%) [1]
TRACHEA GLANDS; DILATION INFILTRATION CELLULAR; MONONUCLEAR CELL	(10) 1 (10%) [1] 1 (10%) [1]	(0)	(0)	(10) 1 (10%) [1]
SPECIAL SENSES SYSTEM None				
URINARY SYSTEM				
KIDNEYS CHRONIC PROGRESSIVE NEPHROPATHY PELVIS; DILATION	(10) 9 (90%) [9] 2 (20%) [2]	(0)	(1) 1 (100%) [1] 1 (100%) [1]	(10) 10 (100%) [10]

Test Compound: 2-Ethylhexyl p-Methoxycinnamate

CAS Number: 5466-77-3

F1 Female : Subchronic Female					
	Treatment Groups (ppm)				
	0	1000	3000	6000	
Disposition Summary					
Animals Initially In Study	10	10	10	10	
Early Deaths					
Scheduled Deaths					
Scheduled sacrifice, terminal (PND 111 - 113)	10	10	10	10	
Number of Animals Examined	10	3	3	10	
Total number litters	10	3	3	10	
ALIMENTARY SYSTEM					
LIVER	(10)	(0)	(1)	(10)	
HEPATODIAPHRAGMATIC NODULE			1 (100%) [1]		
BILE DUCT; HYPERPLASIA				1 (10%) [1]	
INFILTRATION CELLULAR; MONONUCLEAR CELL	2 (20%) [2]			2 (20%) [2]	
INFLAMMATION; FOCAL	1 (10%) [1]			1 (10%) [1]	
INFLAMMATION, CHRONIC				1 (10%) [1]	
SALIVARY GLANDS	(10)	(1)	(0)	(10)	
SUBLINGUAL GLAND; UNILATERAL; INFILTRATION CELLULAR; MONONUCLEAR CELL	1 (10%) [1]				
STOMACH, GLANDULAR	(10)	(0)	(0)	(10)	
GLANDS; CYST				1 (10%) [1]	
GLANDS; DILATION	2 (20%) [2]			1 (10%) [1]	
EROSION				1 (10%) [1]	
CARDIOVASCULAR SYSTEM					
HEART	(10)	(0)	(0)	(10)	
EPICARDIUM; INFLAMMATION, CHRONIC	1 (10%) [1]				

Test Compound: 2-Ethylhexyl p-Methoxycinnamate

CAS Number: 5466-77-3

PARS NERVOSA; DEVELOPMENTAL MALFORMATION 1 (10%) [1] THYROID GLANDS (10) (0) (0) (10) UNILATERAL; CYST 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] ECTOPIC TISSUE, THYMUS 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] GENERAL BODY SYSTEM None 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] GENITAL SYSTEM (10) (2) (2) (10) DUCT; BILATERAL; DILATION (10) (2) (2) (10) DUCT; BILATERAL; DILATION 1 (50%) [1] 1 (10%) [1] 1 (10%) [1] DUCT; UNILATERAL; DILATION 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] UNILATERAL; INFLAMMATION, CHRONIC 3 (30%) [3] 1 (10%) [1] 1 (10%) [1] UNILATERAL; INFLAMMATION, CHRONIC 3 (30%) [3] 1 (10%) [1] 1 (10%) [1] OVARIES (10) (0) (0) (0) (10)		Treatment Groups (ppm)				
PITUITARY GLAND (10) (0) (0) (10) PARS DISTALIS; CYST 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] PARS NERVOSA; DEVELOPMENTAL MALFORMATION 1 (10%) [0) (0) (0) (10) THYROID GLANDS (10) (0) (0) (10) (10%) [1] 1 (10%) [1] THYROID GLANDS 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] GENERAL BODY SYSTEM 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] GENITAL SYSTEM 1 (10%) [1] 1 (50%) [1] 1 (50%) [1] 1 (10%) [1] 1 (10%) [1] DUCT; BILATERAL; DILATION 1 (50%) [1] 1 (50%) [1] 1 (10%) [1] 1 (10%) [1] DUCT; UNILATERAL; DILATION 1 (50%) [1] 1 (50%) [1] 1 (10%) [1] 1 (10%) [1] DUCT; UNILATERAL; INFLAMMATION, CHRONIC 3 (30%) [3] 1 (10%) [1] 1 (10%) [1] UNILATERAL; INFLAMMATION, CHRONIC 3 (30%) [3] 1 (10%) [1] 1 (10%) [1] UNILATERAL; INFLAMMATION, CHRONIC 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] OVARIES (10) (0) (0)<		0	1000	3000	6000	
PARS DISTALIS; CYST 1 (10%) [1] PARS NERVOSA; DEVELOPMENTAL MALFORMATION 1 (10%) [1] THYROID GLANDS (10) (0) (0) (10) THYROID GLANDS 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] GENERAL BODY SYSTEM 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] GENITAL SYSTEM 1 (10%) [1] 1 (50%) [1] 1 (50%) [1] 1 (10%) [1] 1 (10%) [1] DUCT; BILATERAL; DILATION (10) (2) (2) (10) 1 (10%) [1] 1 (ENDOCRINE SYSTEM					
PARS DISTALIS; CYST 1 (10%) [1] PARS NERVOSA; DEVELOPMENTAL MALFORMATION 1 (10%) [1] THYROID GLANDS (10) (0) (0) (10) THYROID GLANDS 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] SENERAL BODY SYSTEM None SENITAL SYSTEM CLITORAL GLANDS (10) (2) (2) (10) DUCT; BILATERAL; DILATION 1 (50%) [1] 1 (10%) [1] 1 (10%) [1] DUCT; UNILATERAL; DILATION 1 (50%) [1] 1 (10%) [1] 1 (10%) [1] DUCT; UNILATERAL; DILATION 1 (50%) [1] 1 (10%) [1] 1 (10%) [1] DUCT; UNILATERAL; DILATION 1 (50%) [1] 1 (10%) [1] 1 (10%) [1] DUCT; UNILATERAL; INFLAMMATION, CHRONIC 3 (30%) [3] 1 (10%) [1] 1 (10%) [1] UNILATERAL; INFLAMMATION, CHRONIC 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] OVARIES (10) (0) (0) (10) OVARIES (10) (0) (10) 1 (10%) [1] UTERUS (10) (0) (0) (10) 1 (10%) [1]	PITUITARY GLAND	(10)	(0)	(0)	(10)	
THYROID GLANDS (10) (0) (0) (10) UNILATERAL; CYST 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] ECTOPIC TISSUE, THYMUS 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] GENERAL BODY SYSTEM None V V SENITAL SYSTEM V V V CLITORAL GLANDS (10) (2) (2) (10) DUCT; BILATERAL; DILATION 1 (50%) [1] 1 (10%) [1] 1 (10%) [1] DUCT; UNILATERAL; INFLATION 1 (50%) [1] 1 (10%) [1] 1 (10%) [1] UNILATERAL; INFLAMMATION CELLULAR; MONONUCLEAR CELL 1 (50%) [1] 1 (10%) [1] 1 (10%) [1] BILATERAL; INFLAMMATION, CHRONIC 3 (30%) [3] 1 (10%) [1] 1 (10%) [1] OVARIES (10) (0) (0) (10) FOLLICLE; UNILATERAL; CYST 2 (20%) [2] 1 (10%) [1] UTERUS (10) (0) (0) (0) ENDOMETRIUM; CYST 1 (10%) [1] 1 (10%) [1] 1 (10%) [1]	PARS DISTALIS; CYST				1 (10%) [1]	
UNILATERAL; CYST 1(10%) [1] 1(10%) [1] 1(10%) [1] ECTOPIC TISSUE, THYMUS 1(10%) [1] 1(10%) [1] SENERAL BODY SYSTEM None CLITORAL GLANDS (10) (2) (2) (10) DUCT; BILATERAL; DILATION 1(50%) [1] 1(50%) [1] 1(10%) [1] DUCT; UNILATERAL; DILATION CELLULAR; MONONUCLEAR CELL UNILATERAL; INFLAMMATION, CHRONIC 3(30%) [3] UNILATERAL; INFLAMMATION, CHRONIC 1(10%) [1] OVARIES (10) (0) (0) (0) (10) FOLLICLE; UNILATERAL; CYST 2(20%) [2] 1(10%) [1] UTERUS (10) (0) (0) (0) (10) ENDOMETRIUM; CYST 1(10%) [1]	PARS NERVOSA; DEVELOPMENTAL MALFORMATION				1 (10%) [1]	
ECTOPIC TISSUE, THYMUS 1 (10%) [1] 1 (10%) [1] GENERAL BODY SYSTEM None GENITAL SYSTEM CLITORAL GLANDS (10) (2) (2) (10) DUCT; BILATERAL; DILATION 1 (50%) [1] 1 (50%) [1] 1 (10%) [1] DUCT; UNILATERAL; DILATION 1 (50%) [1] 1 (10%) [1] 1 (10%) [1] UNILATERAL; INFLAMMATION CELLULAR; MONONUCLEAR CELL 1 (10%) [1] 1 (10%) [1] BILATERAL; INFLAMMATION, CHRONIC 3 (30%) [3] 1 (10%) [1] OVARIES (10) (0) (0) (10) FOLLICLE; UNILATERAL; CYST 2 (20%) [2] 1 (10%) [1] 1 (10%) [1] UTERUS (10) (0) (0) (10) (10) ENDOMETRIUM; CYST 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] 1 (10%) [1]	THYROID GLANDS	(10)	(0)	(0)	(10)	
GENERAL BODY SYSTEM None Clitoreal GLANDS (10) (2) (2) (10) GENITAL SYSTEM 1 (50%) [1] 1 (50%) [1] 1 (10%) [1] 1 (10%) [1] DUCT; BILATERAL; DILATION 1 (50%) [1] 1 (50%) [1] 1 (10%) [1] 1 (10%) [1] DUCT; UNILATERAL; DILATION 1 (50%) [1] 1 (50%) [1] 1 (10%) [1] 1 (10%) [1] UNILATERAL; INFLITRATION CELLULAR; MONONUCLEAR CELL 3 (30%) [3] 1 (10%) [1] 1 (10%) [1] UNILATERAL; INFLAMMATION, CHRONIC 3 (30%) [3] 1 (10%) [1] 1 (10%) [1] OVARIES (10) (0) (0) (10) FOLLICLE; UNILATERAL; CYST 2 (20%) [2] 1 (10%) [1] UTERUS (10) (0) (0) (10) ENDOMETRIUM; CYST 1 (10%) [1] 1 100 10	UNILATERAL; CYST				1 (10%) [1]	
None GENITAL SYSTEM CLITORAL GLANDS (10) (2) (2) (10) DUCT; BILATERAL; DILATION 1 (50%) [1] 1 (50%) [1] 1 (10%) [1] DUCT; UNILATERAL; DILATION 1 (50%) [1] 1 (50%) [1] 1 (10%) [1] UNILATERAL; INFLATION CELLULAR; MONONUCLEAR CELL 1 (10%) [1] 1 (10%) [1] BILATERAL; INFLAMMATION, CHRONIC 3 (30%) [3] 1 (10%) [1] OVARIES (10) (0) (0) (10) FOLLICLE; UNILATERAL; CYST 2 (20%) [2] 1 (10%) [1] 1 (10%) [1] UTERUS (10) (0) (0) (10) ENDOMETRIUM; CYST 1 (10%) [1] 1 (10%) [1] 1 (10%) [1]	ECTOPIC TISSUE, THYMUS	1 (10%) [1]			1 (10%) [1]	
GENITAL SYSTEM CLITORAL GLANDS (10) (2) (2) (10) DUCT; BILATERAL; DILATION 1 (50%) [1] 1 (50%) [1] 1 (10%) [1] DUCT; UNILATERAL; DILATION 1 (50%) [1] 1 (10%) [1] 1 (10%) [1] UNILATERAL; INFLATION CELLULAR; MONONUCLEAR CELL 1 (10%) [1] 1 (10%) [1] BILATERAL; INFLAMMATION, CHRONIC 3 (30%) [3] 1 (10%) [1] UNILATERAL; INFLAMMATION, CHRONIC 1 (10%) [1] 1 (10%) [1] OVARIES (10) (0) (0) (10) FOLLICLE; UNILATERAL; CYST 2 (20%) [2] 1 (10%) [1] 1 (10%) [1] UTERUS (10) (0) (0) (10) (10) ENDOMETRIUM; CYST 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] 1 (10%) [1] 1 (10%) [1]	GENERAL BODY SYSTEM					
CLITORAL GLANDS (10) (2) (2) (10) DUCT; BILATERAL; DILATION 1 (50%) [1] 1 (50%) [1] 1 (10%) [1] DUCT; UNILATERAL; DILATION 1 (50%) [1] 1 (50%) [1] 1 (10%) [1] UNILATERAL; INFLATION CELLULAR; MONONUCLEAR CELL 1 (50%) [1] 1 (50%) [1] 1 (10%) [1] BILATERAL; INFLAMMATION, CHRONIC 3 (30%) [3] 1 (10%) [1] 1 (10%) [1] OVARIES (10) (0) (0) (10) FOLLICLE; UNILATERAL; CYST 2 (20%) [2] 1 (10%) [1] 1 (10%) [1] UTERUS (10) (0) (0) (10) ENDOMETRIUM; CYST 1 (10%) [1] 1 (10%) [1] 1	None					
DUCT; BILATERAL; DILATION 1 (50%) [1] 1 (50%) [1] 1 (10%) [1] DUCT; UNILATERAL; DILATION 1 (50%) [1] 1 (50%) [1] 1 (10%) [1] DUCT; UNILATERAL; DILATION CELLULAR; MONONUCLEAR CELL 1 (10%) [1] 1 (10%) [1] UNILATERAL; INFLAMMATION, CHRONIC 3 (30%) [3] 1 (10%) [1] 1 (10%) [1] UNILATERAL; INFLAMMATION, CHRONIC 3 (30%) [3] 1 (10%) [1] 1 (10%) [1] OVARIES (10) (0) (0) (10) FOLLICLE; UNILATERAL; CYST 2 (20%) [2] 1 (10%) [1] 1 (10%) [1] UTERUS (10) (0) (0) (10) ENDOMETRIUM; CYST 1 (10%) [1] 1 1	GENITAL SYSTEM					
DUCT; UNILATERAL; DILATION 1 (50%) [1] 1 (50%) [1] 1 (10%) [1] UNILATERAL; INFILTRATION CELLULAR; MONONUCLEAR CELL 1 (10%) [1] 1 (10%) [1] BILATERAL; INFLAMMATION, CHRONIC 3 (30%) [3] 1 (10%) [1] 1 (10%) [1] OVARIES (10) (0) (0) (10) FOLLICLE; UNILATERAL; CYST 2 (20%) [2] 1 (10%) [1] 1 (10%) [1] UTERUS (10) (0) (0) (10) ENDOMETRIUM; CYST 1 (10%) [1] 1 (10%) [1] 1 (10%) [1]	CLITORAL GLANDS	(10)	(2)	(2)	(10)	
UNILATERAL; INFILTRATION CELLULAR; MONONUCLEAR CELL 1 (10%) [1] BILATERAL; INFLAMMATION, CHRONIC 3 (30%) [3] UNILATERAL; INFLAMMATION, CHRONIC 1 (10%) [1] OVARIES (10) (0) (0) (10) FOLLICLE; UNILATERAL; CYST 2 (20%) [2] 1 (10%) [1] 1 (10%) [1] UTERUS (10) (0) (0) (10) ENDOMETRIUM; CYST 1 (10%) [1] 1 1	DUCT; BILATERAL; DILATION		1 (50%) [1]	1 (50%) [1]	1 (10%) [1]	
BILATERAL; INFLAMMATION, CHRONIC 3 (30%) [3] 1 (10%) [1] UNILATERAL; INFLAMMATION, CHRONIC 1 (10%) [1] OVARIES (10) (0) (0) (10) FOLLICLE; UNILATERAL; CYST 2 (20%) [2] 1 (10%) [1] 1 (10%) [1] UTERUS (10) (0) (0) (10) ENDOMETRIUM; CYST 1 (10%) [1] 1 1	DUCT; UNILATERAL; DILATION		1 (50%) [1]	1 (50%) [1]	1 (10%) [1]	
UNILATERAL; INFLAMMATION, CHRONIC 1 (10%) [1] OVARIES (10) (0) (10) FOLLICLE; UNILATERAL; CYST 2 (20%) [2] 1 (10%) [1] UTERUS (10) (0) (0) (10) ENDOMETRIUM; CYST 1 (10%) [1] 1 1	UNILATERAL; INFILTRATION CELLULAR; MONONUCLEAR CELL				1 (10%) [1]	
OVARIES (10) (0) (10) FOLLICLE; UNILATERAL; CYST 2 (20%) [2] 1 (10%) [1] UTERUS (10) (0) (0) ENDOMETRIUM; CYST 1 (10%) [1] 1	BILATERAL; INFLAMMATION, CHRONIC	3 (30%) [3]				
FOLLICLE; UNILATERAL; CYST 2 (20%) [2] 1 (10%) [1] UTERUS (10) (0) (0) ENDOMETRIUM; CYST 1 (10%) [1] 1	UNILATERAL; INFLAMMATION, CHRONIC				1 (10%) [1]	
FOLLICLE; UNILATERAL; CYST 2 (20%) [2] 1 (10%) [1] UTERUS (10) (0) (0) (10) ENDOMETRIUM; CYST 1 (10%) [1] 1 1 1	OVARIES	(10)	(0)	(0)	(10)	
ENDOMETRIUM; CYST 1 (10%) [1]	FOLLICLE; UNILATERAL; CYST				1 (10%) [1]	
ENDOMETRIUM; CYST 1 (10%) [1] HEMATOLYMPHOID SYSTEM 1	UTERUS	(10)	(0)	(0)	(10)	
	ENDOMETRIUM; CYST	1 (10%) [1]				
SPLEEN (10) (0) (0) (10)	HEMATOLYMPHOID SYSTEM					
	SPLEEN	(10)	(0)	(0)	(10)	
	None					

Study Number: MOG003B PA10 Test Type: MOG PA10 Route: Dosing in Feed PA10 Species/Strain: Rat/Sprague-Dawley PA10	PA10R: Statistical Analysis of Non-Neoplastic Lesions with Litter Incidence Test Compound: 2-Ethylhexyl p-Methoxycinnamate CAS Number: 5466-77-3		Date Report Requested: 01/14/2020 Time Report Requested: 10:32:51 Lab: RTI	
	F1 Female : Subchronic Femal	e		
		Treatment Groups	s (ppm)	
	0	1000	3000	6000
MUSCULOSKELETAL SYSTEM None				
NERVOUS SYSTEM None				
RESPIRATORY SYSTEM LUNG ALVEOLUS; INFILTRATION CELLULAR, HISTIOCYTE METAPLASIA; OSSEOUS	(10) 4 (40%) [4] 1 (10%) [1]	(0)	(0)	(10) 0 *
NOSE RESPIRATORY EPITHELIUM; CYST	(1) (1) 1 (100%) [1]	(0)	(0)	(0)
TRACHEA GLANDS; DILATION INFILTRATION CELLULAR; MONONUCLEAR CELL	(10)	(0)	(0)	(10) 2 (20%) [2] 2 (20%) [2]
SPECIAL SENSES SYSTEM ZYMBALS GLANDS DUCT; DILATION	(10) 1 (10%) [1]	(0)	(0)	(9)
URINARY SYSTEM KIDNEYS CHRONIC PROGRESSIVE NEPHROPATHY CORTICOMEDULLARY JUNCTION; MINERAL NEPHROBLASTEMATOSIS	(10) 8 (80%) [8] 9 (90%) [9]	(0)	(0)	(10) 8 (80%) [8] 9 (90%) [9] 1 (10%) [1]

PA10R: Statistical Analysis of Non-Neoplastic Lesions with Litter Incidence

Test Compound: 2-Ethylhexyl p-Methoxycinnamate

CAS Number: 5466-77-3

		Treatment C	Groups (ppm)	
	0	1000	3000	6000
Disposition Summary				
Animals Initially In Study	21	23	20	22
Early Deaths				
Unscheduled Sacrifice			1	
Scheduled Deaths				
Scheduled sacrifice, terminal (PND 112 - 114)	21	23	19	22
Number of Animals Examined	5	3	2	2
Total number litters	5	3	2	2
ALIMENTARY SYSTEM				
None				
CARDIOVASCULAR SYSTEM				
None				
ENDOCRINE SYSTEM				
None				
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
LEVATOR ANI PLUS BULBOCAVERNOSUS MUSCLE	(2)	(2)	(0)	(0)
INFLAMMATION, CHRONIC		2 (100%) [2]		
HEMATOLYMPHOID SYSTEM				
None				

Study Number: MOG003B Test Type: MOG Route: Dosing in Feed Species/Strain: Rat/Sprague-Dawley	PA10R: Statistical Analysis of Non-Neoplast Test Compound: 2-Ethylhexyl p CAS Number: 546	Date Report Requested: 01/14/20 Time Report Requested: 10:32:51 Lab: RTI			
	F1 Male : Prenatal Ma	le			
		Treatment Group	os (ppm)		
	0	1000	3000 6000		
MUSCULOSKELETAL SYSTEM None					
NERVOUS SYSTEM None					
RESPIRATORY SYSTEM None					
SPECIAL SENSES SYSTEM None					
URINARY SYSTEM KIDNEYS CHRONIC PROGRESSIVE NEPHROPATH PELVIS; DILATION	(3) IY 3 (100%) [3] 1 (33.3%) [1]	(1) 1 (100%) [1] 1 (100%) [1]	(2) 2 (100%) [2] 2 (100%) [2]	(1) 1 (100%) [1] 1 (100%) [1]	

Test Compound: 2-Ethylhexyl p-Methoxycinnamate

CAS Number: 5466-77-3

F1 Female : Prenatal Female				
		Treatment	: Groups (ppm)	
	0	1000	3000	6000
Disposition Summary				
Animals Initially In Study	21	23	19	22
Early Deaths				
Scheduled Deaths				
Scheduled sacrifice, terminal (GD 21, PND 109 - 132)	21	23	19	22
Number of Animals Examined	3		1	1
Total number litters	3		1	1
ALIMENTARY SYSTEM				
LIVER	(3)	(0)	(1)	(0)
HEPATODIAPHRAGMATIC NODULE	1 (33.3%) [1]		1 (100%) [1]	
HEPATOCYTE; NECROSIS; SUBCAPSULAR	1 (33.3%) [1]			
CARDIOVASCULAR SYSTEM				
None				
ENDOCRINE SYSTEM				
None				
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
None				
HEMATOLYMPHOID SYSTEM				
None				
INTEGUMENTARY SYSTEM				
None				

Study Number: MOG003B Test Type: MOG Route: Dosing in Feed Species/Strain: Rat/Sprague-Dawley	PA10R: Statistical Analysis of Non-Neoplastic Lesions with Litter Incidence Test Compound: 2-Ethylhexyl p-Methoxycinnamate CAS Number: 5466-77-3				quested: 01/14/2020 equested: 10:32:51
	F	1 Female : Prenatal Fema	le		
			Treatment Groups	(ppm)	
		0	1000	3000	6000
MUSCULOSKELETAL SYSTEM None					
NERVOUS SYSTEM None					
RESPIRATORY SYSTEM None					
SPECIAL SENSES SYSTEM None					
URINARY SYSTEM None					

PA10R: Statistical Analysis of Non-Neoplastic Lesions with Litter Incidence

Test Compound: 2-Ethylhexyl p-Methoxycinnamate

CAS Number: 5466-77-3

Date Report Requested: 01/14/2020 Time Report Requested: 10:32:51 Lab: RTI

		Treatment Groups (ppm)				
	0	1000	3000	6000		
Disposition Summary						
Animals Initially In Study	36	46	35	37		
Early Deaths						
Scheduled Deaths						
Scheduled sacrifice, terminal (PND 160 - 167)	36	46	35	37		
Number of Animals Examined	36	46	35	37		
Total number litters	21	24	19	22		
ALIMENTARY SYSTEM						
ESOPHAGUS	(3)	(0)	(0)	(0)		
DILATION	1 (33.3%) [1]					
INTESTINE, COLON	(3)	(0)	(0)	(0)		
DIVERTICULUM	1 (33.3%) [1]					
LIVER	(3)	(2)	(1)	(1)		
HEPATODIAPHRAGMATIC NODULE	1 (33.3%) [1]	2 (100%) [2]	1 (100%) [1]	1 (100%) [1]		
INFILTRATION CELLULAR; MONONUCLEAR CELL	1 (33.3%) [1]					

None

Test Compound: 2-Ethylhexyl p-Methoxycinnamate

		Treatment	Groups (ppm)	
	0	1000	3000	6000
ENDOCRINE SYSTEM				
ADRENAL CORTEX	(36)	(0)	(0)	(37)
UNILATERAL; ANGIECTASIS	1 (2.8%) [1]			
UNILATERAL; HYPERPLASIA, FOCAL				1 (2.7%) [1]
BILATERAL; HYPERTROPHY; FOCAL	1 (2.8%) [1]			
BILATERAL; VACUOLIZATION CYTOPLASMIC, DIFFUSE	8 (22.2%) [6]			3 (8.1%) [3]
ADRENAL MEDULLA	(36)	(0)	(0)	(37)
UNILATERAL; ANGIECTASIS	1 (2.8%) [1]			
PITUITARY GLAND	(36)	(0)	(0)	(37)
PARS DISTALIS; CYST				3 (8.1%) [3]
THYROID GLANDS	(36)	(0)	(0)	(37)
FOLLICLE; DYSPLASIA	1 (2.8%) [1]			
ECTOPIC TISSUE, THYMUS				1 (2.7%) [1]
C-CELL; HYPERPLASIA	1 (2.8%) [1]			

Test Compound: 2-Ethylhexyl p-Methoxycinnamate

CAS Number: 5466-77-3

	F1 Male : Fertility Males				
	Treatment Groups (ppm)				
	0	1000	3000	6000	
GENITAL SYSTEM					
COWPERS GLANDS	(36)	(2)	(0)	(37)	
DEPLETION; SECRETORY	1 (2.8%) [1]				
DORSAL PROSTATE	(36)	(46)	(35)	(37)	
UNILATERAL; INFLAMMATION, SUPPURATIVE		1 (2.2%) [1]	1 (2.9%) [1]	1 (2.7%) [1]	
EPIDIDYMIDES	(36)	(46)	(35)	(37)	
DUCT; EXFOLIATED GERM CELL	3 (8.3%) [3]	1 (2.2%) [1]	1 (2.9%) [1]	1 (2.7%) [1]	
GRANULOMA SPERM				1 (2.7%) [1]	
HYPOSPERMIA		1 (2.2%) [1]		2 (5.4%) [2]	
INFILTRATION CELLULAR; MONONUCLEAR CELL	4 (11.1%) [4]		1 (2.9%) [1]	6 (16.2%) [5]	
PREPUTIAL GLANDS	(36)	(6)	(2)	(37)	
DUCT; BILATERAL; DILATION	10 (27.8%) [8]	4 (66.7%) [2]	1 (50%) [1]	10 (27%) [9]	
DUCT; UNILATERAL; DILATION	6 (16.7%) [6]	2 (33.3%) [2]	1 (50%) [1]	7 (18.9%) [6]	
BILATERAL; INFLAMMATION, CHRONIC	5 (13.9%) [5]			3 (8.1%) [2]	
UNILATERAL; INFLAMMATION, CHRONIC	2 (5.6%) [2]	2 (33.3%) [2]		2 (5.4%) [2]	
BILATERAL; INFLAMMATION, SUPPURATIVE	2 (5.6%) [2]	1 (16.7%) [1]		2 (5.4%) [2]	
UNILATERAL; INFLAMMATION, SUPPURATIVE	3 (8.3%) [3]	1 (16.7%) [1]		3 (8.1%) [3]	
TESTES	(36)	(46)	(35)	(37)	
GERMINAL EPITHELIUM; ATROPHY		1 (2.2%) [1]		2 (5.4%) [2]	
GERM CELL; DEGENERATION	5 (13.9%) [5]	1 (2.2%) [1]	4 (11.4%) [3]		
GRANULOMA SPERM				1 (2.7%) [1]	
VENTRAL PROSTATE	(36)	(46)	(35)	(37)	
ACINUS; UNILATERAL; ATROPHY				1 (2.7%) [1]	
BILATERAL; INFILTRATION CELLULAR; MONONUCLEAR CELL	2 (5.6%) [2]		2 (5.7%) [2]		
UNILATERAL; INFILTRATION CELLULAR; MONONUCLEAR CELL	1 (2.8%) [1]	3 (6.5%) [3]	2 (5.7%) [2]	3 (8.1%) [3]	
BILATERAL; INFLAMMATION, CHRONIC	4 (11.1%) [3]	8 (17.4%) [8]	2 (5.7%) [2]	9 (24.3%) [7]	
UNILATERAL; INFLAMMATION, CHRONIC	1 (2.8%) [1]	2 (4.3%) [2]	1 (2.9%) [1]	2 (5.4%) [2]	

Study Number: MOG003B Test Type: MOG Route: Dosing in Feed Species/Strain: Rat/Sprague-Dawley	Test Compound: 2-Ethylhexyl p-M	PA10R: Statistical Analysis of Non-Neoplastic Lesions with Litter Incidence Test Compound: 2-Ethylhexyl p-Methoxycinnamate CAS Number: 5466-77-3		Date Report Requested: 01/14/2020 Time Report Requested: 10:32:51 Lab: RTI	
	F1 Male : Fertility Males				
		Treatment Grou	os (ppm)		
	0	1000	3000	6000	
HEMATOLYMPHOID SYSTEM None					
INTEGUMENTARY SYSTEM SKIN ULCER	(0)	(1) 1 (100%) [1]	(0)	(0)	
MUSCULOSKELETAL SYSTEM None					
NERVOUS SYSTEM None					
RESPIRATORY SYSTEM LUNG INFLAMMATION, GRANULOMATOUS SMOOTH MUSCLE; ARTERY; PROLIFERA	(3) 1 (33.3%) [1] 1 (33.3%) [1]	(0)	(0)	(0)	
SPECIAL SENSES SYSTEM None					
URINARY SYSTEM KIDNEYS CHRONIC PROGRESSIVE NEPHROPATH PELVIS; DILATION	(3) 2 (66.7%) [2] 1 (33.3%) [1]	(1) 1 (100%) [1] 1 (100%) [1]	(2) 2 (100%) [2] 2 (100%) [2]	(0)	

PA10R: Statistical Analysis of Non-Neoplastic Lesions with Litter Incidence

Test Compound: 2-Ethylhexyl p-Methoxycinnamate

CAS Number: 5466-77-3

F1 Female : Fertility Females					
	Treatment Groups (ppm)				
	0	1000	3000	6000	
Disposition Summary					
Animals Initially In Study	36	46	35	38	
Early Deaths					
Euthanized, moribund				1	
Unscheduled Sacrifice			1		
Scheduled Deaths					
Scheduled sacrifice, terminal (GD 44 - 49, LD 14 - 28, PND 151 - 154)	36	46	34	37	
Number of Animals Examined	32	5	2	25	
Total number litters	19	5	2	19	
ALIMENTARY SYSTEM					
LIVER	(4)	(0)	(0)	(1)	
HEPATODIAPHRAGMATIC NODULE	2 (50%) [2]				
OVAL CELL; PERIPORTAL; HYPERPLASIA				1 (100%) [1]	
HEPATOCYTE; PERIPORTAL; HYPERTROPHY				1 (100%) [1]	
CARDIOVASCULAR SYSTEM					
HEART	(2)	(0)	(1)	(0)	
CARDIOMYOPATHY			1 (100%) [1]		
ENDOCRINE SYSTEM					
ADRENAL CORTEX	(26)	(0)	(0)	(23)	
UNILATERAL; HYPERTROPHY; FOCAL	1 (3.8%) [1]				
PITUITARY GLAND	(26)	(0)	(0)	(23)	
PARS DISTALIS; CYST				1 (4.3%) [1]	
THYROID GLANDS	(26)	(0)	(0)	(23)	
ECTOPIC TISSUE, THYMUS	1 (3.8%) [1]				

Test Type: MOG Route: Dosing in Feed Species/Strain: Rat/Sprague-Dawley	Test Compound: 2-Ethylhexyl p-Methoxycinnamate CAS Number: 5466-77-3		Time Report Requested: 10:32:51 Lab: RTI					
F1 Female : Fertility Females								
		Treatment G	roups (ppm)					
	0	1000	3000	6000				
GENERAL BODY SYSTEM None								
GENITAL SYSTEM								
CLITORAL GLANDS DUCT; UNILATERAL; DILATION UNILATERAL; INFLAMMATION, SUPPURATIVE	(2)	(1) 1 (100%) [1] 1 (100%) [1]	(1) 1 (100%) [1]	(0)				
OVARIES	(26)	(0)	(0)	(23)				
PARAOVARIAN; UNILATERAL; CYST	1 (3.8%) [1]							
UTERUS	(26)	(3)	(0)	(23)				
ENDOMETRIUM; CYST	3 (11.5%) [3]							
CYST		2 (66.7%) [2]		1 (4.3%) [1]				
DECIDUAL REACTION				1 (4.3%) [1]				
MINERAL	1 (3.8%) [1]			3 (13%) [3]				
HEMATOLYMPHOID SYSTEM None								
INTEGUMENTARY SYSTEM								
MAMMARY GLANDS	(2)	(1)	(0)	(0)				
SKIN	(2)	(0)	(0)	(1)				
PUSTULE				1 (100%) [1]				
MUSCULOSKELETAL SYSTEM None								
NERVOUS SYSTEM None								
RESPIRATORY SYSTEM None								

Study Number: MOG003B

Date Report Requested: 01/14/2020

Study Number: MOG003B Test Type: MOG Route: Dosing in Feed Species/Strain: Rat/Sprague-Dawley	Test Compound: 2-Ethylhexyl p-M	R: Statistical Analysis of Non-Neoplastic Lesions with Litter Incidence Test Compound: 2-Ethylhexyl p-Methoxycinnamate CAS Number: 5466-77-3			
	F1 Female : Fertility Femal	les			
		Treatment Groups (ppm)			
	0	1000	3000	6000	
SPECIAL SENSES SYSTEM None					
URINARY SYSTEM					
KIDNEYS	(2)	(0)	(0)	(1)	
CHRONIC PROGRESSIVE NEPHROPATHY	2 (100%) [2]			1 (100%) [1]	
PELVIS; DILATION				1 (100%) [1]	
CORTICOMEDULLARY JUNCTION; MINERAL	1 (50%) [1]			1 (100%) [1]	

PA10R: Statistical Analysis of Non-Neoplastic Lesions with Litter Incidence

Test Compound: 2-Ethylhexyl p-Methoxycinnamate

CAS Number: 5466-77-3

	F2 Male				
	Treatment Groups (ppm)				
	0	1000	3000	6000	
Disposition Summary					
Animals Initially In Study	94	135	86	96	
Early Deaths					
Scheduled Deaths	• •				
Scheduled sacrifice, terminal (PND 28)	94	135	86	96	
Number of Animals Examined	8	3	2	6	
Total number litters	5	3	2	5	
ALIMENTARY SYSTEM					
LIVER	(2)	(2)	(0)	(3)	
HEPATODIAPHRAGMATIC NODULE		2 (100%) [2]		3 (100%) [2]	
CARDIOVASCULAR SYSTEM					
None					
ENDOCRINE SYSTEM					
None					
GENERAL BODY SYSTEM					
None					
GENITAL SYSTEM					
TESTES	(4)	(1)	(2)	(1)	
IMMATURE				1 (100%) [1]	
HEMATOLYMPHOID SYSTEM					
None					
INTEGUMENTARY SYSTEM					
SKIN	(0)	(0)	(0)	(1)	
SUBCUTANEOUS TISSUE; INFLAMMATION; SUPPURATIVE				1 (100%) [1]	

Study Number: MOG003B Test Type: MOG Route: Dosing in Feed Species/Strain: Rat/Sprague-Dawley	PA10R: Statistical Analysis of Non-Neoplastic Lesions with Litter Incidence Test Compound: 2-Ethylhexyl p-Methoxycinnamate CAS Number: 5466-77-3			Date Report Requested: 01/14/2020 Time Report Requested: 10:32:51 Lab: RTI	
		F2 Male			
			Treatment Groups	(ppm)	
		0	1000	3000	6000
MUSCULOSKELETAL SYSTEM None					
NERVOUS SYSTEM None					
RESPIRATORY SYSTEM None					
SPECIAL SENSES SYSTEM None					
URINARY SYSTEM None					

PA10R: Statistical Analysis of Non-Neoplastic Lesions with Litter Incidence

Test Compound: 2-Ethylhexyl p-Methoxycinnamate

	F2 Female					
		Treatment Groups (ppm)				
	0	1000	3000	6000		
Disposition Summary						
Animals Initially In Study	110	125	85	102		
Early Deaths						
Scheduled Deaths						
Scheduled sacrifice, terminal (PND 28)	110	125	85	102		
Number of Animals Examined	2		1	1		
Total number litters	1		1	1		
ALIMENTARY SYSTEM						
LIVER	(2)	(0)	(1)	(1)		
HEPATODIAPHRAGMATIC NODULE	2 (100%) [1]		1 (100%) [1]	1 (100%) [1]		
CARDIOVASCULAR SYSTEM						
None						
ENDOCRINE SYSTEM						
None						
GENERAL BODY SYSTEM						
None						
GENITAL SYSTEM						
None						
HEMATOLYMPHOID SYSTEM						
None						
INTEGUMENTARY SYSTEM						
None						

Study Number: MOG003B Test Type: MOG Route: Dosing in Feed Species/Strain: Rat/Sprague-Dawley	PA10R: Statistical Analysis of Non-Neoplastic Lesions with Litter Incidence Test Compound: 2-Ethylhexyl p-Methoxycinnamate CAS Number: 5466-77-3				quested: 01/14/2020 equested: 10:32:51
		F2 Female			
			Treatment Groups	(ppm)	
		0	1000	3000	6000
MUSCULOSKELETAL SYSTEM None					
NERVOUS SYSTEM None					
RESPIRATORY SYSTEM None					
SPECIAL SENSES SYSTEM None					
URINARY SYSTEM None					

Date Report Requested: 01/14/2020 Time Report Requested: 10:32:51 Lab: RTI

LEGEND

Number of animals examined for each tissue shown in parentheses. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion. The exception to this is if statistical significance is found for a lesion and the control group has no animals with the lesion then a 0 is included for the control group on the table for that lesion.

Number of animals with observation reported with percent incidence in parentheses

Number of litters with observations shown in square brackets for F1 and F2 animals. F1 litter incidence based on the number of F0 dams; F2 litter incidence based on number of F1 dams.

Trend significance is reported only for those organs that were fully examined in the control group plus two or more other dose groups. For organs that were fully examined in just the control and one other dose group, only the pairwise significance is reported.

Statistical analysis of the F1 Subchronic cohort was performed by Cochran-Armitage (trend) and Fisher Exact (pairwise) tests.

Statistical analysis for the F1 Fertility animals was performed by Cochran-Armitage test with a poly-3 adjustment for age and a Rao-Scott modification for the random effect due to litter.

All trend and pairwise p-values are reported as one-sided.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at P <= 0.05

** Statistically significant at P <= 0.01

Non-pregnant females from the F0 and F1 generations are included in the analysis.

SD - Study Day; GD - Gestation Day; LD - Lactation Day; PND - Postnatal Day, adults post-weaning

** END OF REPORT **